Presentation is loading. Please wait.

Presentation is loading. Please wait.

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features  Min-Woong Kang, MD, PhD, Eung-Sirk.

Published byGuido Goossens Modified over 5 years ago

Similar presentations

Presentation on theme: "Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features  Min-Woong Kang, MD, PhD, Eung-Sirk."— Presentation transcript:

1 Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features  Min-Woong Kang, MD, PhD, Eung-Sirk Lee, MD, Jisuk Jo, MS, Joungho Han, MD, PhD, Yong Chan Ahn, MD, PhD, Hong Kwan Kim, MD, Yong Soo Choi, MD, Kwhanmien Kim, MD, PhD, Young Mog Shim, MD, PhD, Jhingook Kim, MD  Journal of Thoracic Oncology  Volume 4, Issue 12, Pages (December 2009) DOI: /JTO.0b013e3181b9cd7f Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan-Meier curves of overall survival and recurrence-free survival with confidence intervals (dotted line) of patients with Masaoka stage III thymomas (n = 59). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181b9cd7f) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan-Meier curve of overall survival by the WHO classification (A), completeness of resection (B). R0: complete resection with negative microscopic margins; R1: incomplete resection on microscopic examination (R1); and R2: macroscopically incomplete resection. Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181b9cd7f) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Kaplan-Meier curve of recurrence-free survival by size (A), WHO classification (B), number of organs invaded (C), and pericardium invasion (D). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181b9cd7f) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Kaplan-Meier curve for overall survival and recurrence-free survival of groups A and B. Group A (limited invasion group, single organ invasion + two organs invaded, and tumor less than 6.5 cm); group B (extensive invasion group, two organs invaded, and tumor 6.5 cm or larger + ≥ three organs invaded). Panel A (R0 resection) and panel B (R0 + R1 resection). Journal of Thoracic Oncology 2009 4, DOI: ( /JTO.0b013e3181b9cd7f) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features  Min-Woong Kang, MD, PhD, Eung-Sirk."

Similar presentations

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Thymic Epithelial Tumors: Prognostic Determinants Among Clinical, Histopathologic, and Computed Tomography Findings  Jung Won Moon, MD, Kyung Soo Lee,

Thymic Epithelial Tumors: Prognostic Determinants Among Clinical, Histopathologic, and Computed Tomography Findings  Jung Won Moon, MD, Kyung Soo Lee,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
E13-01: Insights into thymic epithelial tumor: pathology

E13-01: Insights into thymic epithelial tumor: pathology
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119  Wallace Akerley, MD, Jason McCoy, MS, Paul J.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Similar presentations

Ads by Google